Classify the Disease Define the Risk
Better informed decisions for the management of multiple myelomaLearn about MyPRS®
Is the only clinically validated, comprehensive commercially available gene expression profile for multiple myeloma
Is validated in more than 4500 patients in 4 countries and in 17 unique patient data sets; reported in numerous peer-reviewed publications
Provides a detailed analysis already interpreted for you; over 1000 genes produce clear and actionable results
As Published In:
- BMC Medical Geonomics
- Mayo Clinic
- British Journal of Haematology
What is MyPRS® ?
Myeloma Prognostic Risk Signature
Not just a gene expression profile but a panel of tests delivering more information about an individual patient's Multiple Myeloma than any other test alone or in combination.
Analyzes the expression of 70 genes to provide two personalized outputs to display your patient’s individual disease prognosis: 5-year probability of relapse and 5-year probability of Overall Survival READ MORE»
Analyzes the expression of 1516 genes to determine Chromosomal Abnormalities. Virtual Karyotype-Trisomy (additions) or monosomy (deletions) and Virtual FISH- Translocations.
Analyzes 700 genes and was derived from 414 newly diagnosed MM patients and based on concordant gene expression signatures, predominantly driven by recurrent translocations and hyperdiploidy, MM was characterized as belonging to 7 distinct molecular subtypes. READ MORE»
Get the advantage
Take the subjectivity out of multiple myeloma management.
Signal Genetics, Inc., is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better informed decisions concerning the care of their patients suffering from cancer.
Offering the only commercially available test of its kind, MyPRS
From its state-of-the-art, CLIA-certified reference laboratory located in Little Rock, Arkansas, Signal Genetics offers the unique flagship product, Myeloma Prognostic Risk Signature, or MyPRS. This test analyzes a whole-genome expression profile (GEP) of the patient's tumor cells and uses proprietary, well-validated algorithms to generate a personalized prognosis assessment and molecular characterization of the disease.